FDANews
FDAnews Device Daily Bulletin

BiologicTx Desensitization Data Shows Reduced Time to Transplant, Lower Risk of AMR Post-Transplant

Sept. 23, 2016

BiologicTx has released positive three-year clinical outcomes data for patients treated with desensitization therapy resulting in a successful transplant.

In all 421 patients, the primary therapeutic modality was IVIg 2g/kg per month infused through BiologicTx therapeutic services in an outpatient setting.

According to clinical results, of 361 patients, 111 have reached transplant, achieving an effective transplant rate of 30.7 percent. — Cynthia Jessup

View today's stories